[HTML][HTML] Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
[HTML][HTML] The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …
worldwide, critically impacting public health systems. A number of already approved and …
[HTML][HTML] Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label …
ZF Udwadia, P Singh, H Barkate, S Patil… - International Journal of …, 2021 - Elsevier
Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …
[HTML][HTML] COVID-19: characteristics and therapeutics
R Chilamakuri, S Agarwal - Cells, 2021 - mdpi.com
Novel coronavirus (COVID-19 or 2019-nCoV or SARS-CoV-2), which suddenly emerged in
December 2019 is still haunting the entire human race and has affected not only the …
December 2019 is still haunting the entire human race and has affected not only the …
[HTML][HTML] Peptide and peptide-based inhibitors of SARS-CoV-2 entry
To date, no effective vaccines or therapies are available against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus …
syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus …
DrugCentral 2021 supports drug discovery and repositioning
DrugCentral is a public resource (http://drugcentral. org) that serves the scientific community
by providing up-to-date drug information, as described in previous papers. The current …
by providing up-to-date drug information, as described in previous papers. The current …
A global picture: therapeutic perspectives for COVID-19
VP Chavda, C Kapadia, S Soni, R Prajapati… - …, 2022 - Taylor & Francis
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
[HTML][HTML] Broad-spectrum antiviral strategies and nucleoside analogues
RJ Geraghty, MT Aliota, LF Bonnac - Viruses, 2021 - mdpi.com
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such
as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory …
as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory …
[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
[HTML][HTML] Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection
BM Sahoo, BVV Ravi Kumar, J Sruti… - Frontiers in Molecular …, 2021 - frontiersin.org
Drug repurposing is also termed as drug repositioning or therapeutic switching. This method
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …